Astrazeneca Pharma India Ltd.
ASTRAZEN Share PricePharmaceuticals & Drugs
₹9,122
-33 (-0.4%)
As on December 15, 2025
Exchange Scrips: BSE506820NSEASTRAZENISININE203A01020
Market Cap ₹ 22,834 Cr
P/E Ratio 197.04
Dividend Yield 0.18 %
Performance
Market performance
Open9,050
High9,179.5
Volumes3,842
Prev9,122
Low9,050
As on2025-12-15
Historical performance
1 Year High10,691
3 Year High10,691
5 Year High10,691
1 Year Low6,312.75
3 Year Low3,098
5 Year Low2,445.7
Fundamentals
Company Valuation
Market Cap (₹Cr)
22,834
Face Value (₹)
2
P/E Ratio
197.04
Dividend Yield
0.18 %
Investment Returns
1 Year
37.7%
3 Years
170.2%
5 Years
105.7%
10 Years
742.2%
Technicals
| Indicators | Value | Signal |
|---|---|---|
| 5-DMA | 9,093.4 | Bullish |
| 10-DMA | 9,120.05 | Bullish |
| 20-DMA | 9,083.55 | Bullish |
| 50-DMA | 9,205.68 | Bearish |
| 100-DMA | 9,018.64 | Bullish |
| 200-DMA | 8,770.88 | Bullish |
Shareholding Pattern
| Field | Sep-2025 | Jun-2025 | Mar-2025 | Dec-2024 | Sep-2024 |
|---|---|---|---|---|---|
| Promoters | 1 | 1 | 1 | 1 | 1 |
| Foreign Investors | 1 | 1 | 1 | 1 | 1 |
| Domestic Investors | --- | --- | --- | --- | --- |
| Public Investors | 32913 | 34377 | 32465 | 27321 | 27614 |
| Government | --- | --- | --- | --- | --- |
Financials
Below figures are in Rs. Crores
Balance Sheet
Below figures are in Rs. Crores
Cash Flow
Below figures are in Rs. Crores
0%
Negative
Neutral
Positive
- The stock has a PE ratio of 197.04.
- 3Y Stock Price CAGR of the stock is 39.0.
- The stock has a beta of 0.4.
- In the last financial year, the company had an EBITDA of ₹2946 Million.
- The company generated revenue of ₹17163 Million in the previous financial year.
Astrazeneca Pharma India Ltd.
9122-33 (-0.4%)
₹
Investment Amount: ₹ 1000000
Current Value: ₹ 1381597.9
No. of Shares: 151 (Approx)
Performance:38.2%
P/L: ₹381597.9
Top Gainers
| Symbol | Change% |
|---|---|
| TAINWALCHM | 191.9(20%) |
| TVVISION | 9.32(20%) |
| REFEX | 299.4(18%) |
| MAHAPEXLTD | 111.44(17%) |
| VIPULLTD | 11.92(16%) |
Peer Comparison
Get Your Portfolio Reviewed
